Fluconazole: profile and news

A Potential HIV Prophylactic?  Feb 7, 2006
Gilead Sciences’ anti-HIV drug Truvada protected monkeys from becoming infected with a very close relative of the human HIV virus, suggesting that the drug ... - Red Herring,

Drug combination prevents HIV infection in monkeys  Feb 6, 2006
Dr. Walid Heneine of the Centers for Disease and Prevention studied rhesus monkeys that were injected with a version of Truvada -- Gilead Sciences Inc.'s once-a ... - Reuters

Drug Combination Prevents HIV in Monkeys  Feb 7, 2006
Dr. Walid Heneine of the Centers for Disease Control and Prevention studied rhesus monkeys that were injected with a version of Truvada and Emtriva. ... - All Headline News

Drug combination prevents HIV infection in animal study  Feb 8, 2006
The rhesus monkeys were injected with a version of Truvada, Gilead Science's once-daily pill that includes its drugs Viread and Emtriva. ... - The Advocate,

Medical Report  Feb 4, 2006
BOSTON - Anti-HIV treatment consisting of efavirenz (Sustiva) with tenofovir and FTC (Truvada) created significantly more fatty deposits on limbs than for ... - Houstonvoice.com,

CytoDyn Gets Greenlight from Its Investigators for China Joint ...  Feb 27, 2006
...disease, Cytolin(R) might extend the useful life of the antiretroviral drugs currently used to treat HIV/AIDS, such as Emtriva(R) and Truvada(R) manufactured ... - Business Wire (press release),

Daily Injection of Common Antiretroviral Drugs Found To Protect ...  Feb 8, 2006
...a researcher at the agency, looked at rhesus monkeys that were injected with a version of Gilead Sciences' antiretroviral therapy Truvada -- which contains ... - Kaiser network.org,

CytoDyn Gets Greenlight from Its Investigators for China Joint ...  Feb 27, 2006
...disease, Cytolin® might extend the useful life of the antiretroviral drugs currently used to treat HIV/AIDS, such as Emtriva® and Truvada® manufactured by ... - Financial News USA (press release),

MSF Calls on Gilead To Increase Access to Reduced-Cost Viread  Feb 9, 2006
...the program to 97 developing countries, and in August 2005 the company announced it would lower the prices of Viread and its antiretroviral Truvada by 31% and ... - Kaiser network.org,

Biotech Investing for the Long Haul  Feb 22, 2006
Even after Viread and Truvada were approved, the company continued test these drugs against those of key competitors, gathering the strongest case possible for ... - Morningstar.com,

Merck, Gilead Drugs Offer Hope Against Resistant HIV (Update1)  Feb 7, 2006
...rapidly. Gilead's Truvada, introduced a year and half ago, generates 41 percent of the company's $1.39 billion in HIV drug revenue. ... - Bloomberg

Full Text  Feb 16, 2006
In a new study of the same design, CDC's Walid Heneine and co-workers added FTC to tenofovir (a combination drug sold commercially as Truvada) and found that ... - Science Magazine (subscription)

MSF Calls on Gilead To Increase Access to Reduced-Cost Viread  09 Feb 2006
...the program to 97 developing countries, and in August 2005 the company announced it would lower the prices of Viread and its antiretroviral Truvada by 31% and ... - Kaiser network.org,

Truvada Boosts Gilead's Revenue  Jan 30, 2006
...fourth-quarter revenue jumped 65% from a year ago, while product sales climbed for the ninth straight quarter as a result of the HIV drug Truvada and growth ... - TheStreet.com

Fat loss associated with Combivir but not Truvada  Jan 23, 2006
Individuals who took a year of anti-HIV treatment consisting of efavirenz (Sustiva) with tenofovir and FTC (Truvada) had significantly more limb fat than those ... - Aidsmap,

ICAAC: Switching from Combivir to Truvada has benefits for ...  Jan 11, 2006
...the chances of a patient achieving a viral load below 50 copies/ml, according to a study involving Gilead Sciences, the manufacturers of Truvada which was ... - Aidsmap,

Gilead and BMS to seek regulatory approval for efavirenz, Truvada ...  Jan 10, 2006
...and Bristol Myers Squibb (BMS) announced that they now have data showing that a fixed dose combination pill combining Gilead’s Truvada (tenofovir and FTC ... - Aidsmap,

Gilead Sciences Announces Fourth Quarter and Full Year 2005 ...  Jan 30, 2006
This growth continues to be driven primarily by Gilead's HIV product franchise, including the continued strong uptake of Truvada(R) (emtricitabine and ... - Genetic Engineering News,

Medical Report  Feb 3, 2006
BOSTON - Anti-HIV treatment consisting of efavirenz (Sustiva) with tenofovir and FTC (Truvada) created significantly more fatty deposits on limbs than for ... - Washington Blade,

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
...(GILD.O: Quote, Profile, Research) on Monday said its fourth-quarter profit more than doubled due to higher demand for Truvada, its once-a-day pill to treat HIV ... - Reuters

Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ...  Jan 18, 2006
Viread and Emtriva are often prescribed together as a fixed-dose combination tablet called Truvada(R) (emtricitabine and tenofovir disoproxil fumarate), which ... - Genetic Engineering News,

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
...on Monday said its fourth-quarter profit more than doubled due to higher demand for Truvada, its once-a-day pill to treat HIV, although some analysts had hoped ... - ABC News

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
...on Monday said its fourth-quarter profit more than doubled due to increased demand for Truvada, its once-a-day pill to treat HIV, but at least one analyst was ... - ABC News

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
...(GILD.O: Quote, Profile, Research) on Monday said its fourth-quarter profit more than doubled due to increased demand for Truvada, its once-a-day pill to treat ... - Reuters

Cheer or tax record oil-industry profits? We report, you decide  Jan 30, 2006
Gilead said sales were up for its Truvada pill, which combines two medications that fight HIV. ... Truvada sales accounted for $191.1 million of that. ... - San Jose Mercury News,

Zoek in het archief  Jan 9, 2006
BMY) Bristol-Myers Squibb and Gilead Announce Data Supporting Bioequivalence for Single-Pill Fixed-Dose Regimen of Sustiva and Truvada Pharmaceutical Writers ... - Netherlands Corporate News (persbericht),

Bristol-Myers Squibb and Gilead Announce Data Supporting ...  Jan 9, 2006
...bioequivalence of a new formulation of the fixed-dose combination of Bristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R) (emtricitabine and ... - Business Wire (press release),

Bristol-Myers Squibb and Gilead Announce Data Supporting ...  Jan 9, 2006
...of a new formulation of the fixed-dose combination ofBristol-Myers Squibb's Sustiva(R) (efavirenz) and Gilead's Truvada(R)(emtricitabine and tenofovir ... - Finanzen.net,

HIV drug sales lift Gilead profits  Jan 31, 2006
...said fourth-quarter profit more than doubled as sales climbed for the Foster City company's Truvada medicine, which combines two HIV drugs into a single, once-a ... - Inside Bay Area,

Data Comparing Viread(R) and Emtriva(R) to Combivir(R) as Part of ...  Jan 18, 2006
Viread and Emtriva are often prescribed together as a fixed-dosecombination tablet called Truvada(R) (emtricitabine and tenofovirdisoproxil fumarate), which ... - Finanzen.net,

GILEAD SCIENCES INC  Jan 31, 2006
...shares, followed by a rally? It seems that sales of its HIV/AIDS drug Truvada were a bit weaker than many had hoped. The drug hit the ... - Reuters

Gilead 4th-qtr profit doubles but stock falls  Jan 30, 2006
LOS ANGELES - Gile - ) on Monday said its fourth-quarter profit more than doubled due to increased demand for Truvada, its once-a-day pill to treat HIV , but ... - Herald News Daily,

Gilead fourth-quarter profit more than doubles  Jan 30, 2006
Overall HIV drug sales rose 47 percent during the quarter, including $191.1 million in sales of Truvada, a two-drug combination HIV pill launched last year. ... - Reuters

TECH TICKER  Jan 31, 2006
Gilead Sciences said Monday that fourth-quarter profit more than doubled as sales climbed for the company's Truvada medicine, which combines two HIV drugs into ... - San Jose Mercury News,

Merck, Gilead Drugs Offer New Approach to Tackle HIV Resistance  Feb 6, 2006
...rapidly. Gilead's Truvada, introduced a year and half ago, generates 41 percent of the company's $1.39 billion in HIV drug revenue. ... - Bloomberg

Gilead Sciences' Profit More Than Doubles  Jan 31, 2006
Gilead Sciences Inc.'s said fourth-quarter profit more than doubled as sales climbed for the company's Truvada medicine, which combines two HIV drugs into a ... - Los Angeles Times,

Gilead HIV drug shows promise  Jan 19, 2006
Those two are already sold as a combination pill called Truvada. ... But Truvada has recently surpassed it in market share, a Gilead spokesman said. ... - San Francisco Chronicle,

Companies announce success in forming single-pill anti-HIV regimen  Jan 9, 2006
The companies on Monday announced they’ve successfully combined the drugs Sustiva and Truvada into a single formulation. Truvada ... - The Advocate,

Study: Gilead's HIV combo beats Glaxo's  Jan 18, 2006
...is a paid consultant to both Gilead and Glaxo, noted that, since the study began, Viread and Emtriva have been combined into one pill called Truvada, "so it's ... - United Press International

Study Rates Generation Of New AIDS Cocktails  Jan 19, 2006
Both Gilead and Glaxo's Combivir combine Sustiva, a drug made by Bristol-Myers Squibb. The Gilead pill is made up of Truvada and Sustiva. ... - 365Gay.com

Gilead, Bristol Won't Quit on HIV Drug  Jan 9, 2006
The combination pill contains Sustiva from Bristol-Myers and Truvada from Gilead. Truvada is a once-a-day combination of Emtriva and Viread from Gilead. ... - TheStreet.com

New HIV Drug Regimen More Effective Than Existing Therapy  Jan 18, 2006
...emtricitabine (Emtriva) and efavirenz (Sustiva) -- are now available in just two pills (Sustiva plus a Viread-Emtriva combination called Truvada.) Soon, the ... - Forbes

New HIV Regimen Outperforms Gold Standard  Jan 19, 2006
The Viread/Emtriva combination is now available as a single pill, dubbed Truvada, which reduces the so-called pill burden to two a day. ... - CNN

Gilead Says Combo Drug Moves Forward  Jan 9, 2006
...requirement for regulatory approval. The pill includes Bristol-Myers' Sustiva drug with Gilead's Truvada in a fixed dose. It uses a ... - MSN Money

Drug Firms To Produce Single Pill AIDS Treatment  Jan 20, 2006
...the AIDS drugs market. The combined Viread and Emtriva medicines are already in the market under the name of Truvada. More than 40 ... - MedIndia,

Bristol-Meyers Squibb, Gilead advance single-dose HIV drug  Jan 12, 2006
The new combination drug will combine Bristol-Meyers’ Sustiva with Gilead’s Truvada in a one-pill fixed dose, using a process called “bi-layer ... - Dallas Voice,

Analysts' Stock Picks: Part 1  Jan 23, 2006
Gilead Sciences (GILD ): Werber describes Gilead as a "good large cap stock for growth investors." The company's top seller, Truvada, combines two of the ... - BusinessWeek

Eye On Stocks For Tuesday, Jan. 31  Jan 30, 2006
Global sales of HIV drug Truvada came in at $191 million, short of the Wall Street consensus estimate of $202 million with lower-than-expected US sales. ... - Forbes

Gilead 4Q profit rises on AIDS drug sales  Jan 30, 2006
Gilead said sales of HIV products rose 53 percent to $1.39 billion, led by its newest therapy, Truvada, which accounted for 50 percent of sales. ... - BusinessWeek

Gilead HIV drug combo beats GSK rival in phase III trial  Jan 20, 2006
Viread and Emtriva are often prescribed together as a fixed-dose combination tablet called Truvada (emtricitabine and tenofovir disoproxil fumarate), which ... - Pharmaceutical Business Review

Health Beat  Jan 26, 2006
HIVers already can take the regimen as two pills, one of Sustiva and another of Truvada, which contains tenofovir and emtricitabine. ... - Bay Area Reporter,

Drug price reduction makes Aids manageable  Jan 25, 2006
In April, Aspen secured a non-exclusive licensing and distribution deal with Gilead Sciences to make generic versions of the ARVs, Truvada (a combination of ... - iAfrica.com,

Study Sets New Gold Standard For Initial Antiretroviral Treatment ...  Jan 25, 2006
Gallant notes that this regimen became even simpler in 2004, when tenofovir and emtricitabine were combined into a single pill, called Truvada. ... - Science Daily (press release)

Gilead income nearly triples  Jan 30, 2006
The company's HIV treatments marked their ninth consecutive quarter of sales growth, especially for Gilead's Truvada, which was put on the market in August 2004 ... - Investor's Business Daily (subscription)

Brisol-Myers, Gilead advance combo AIDS treatment  Jan 9, 2006
The companies said the new data supports bioequivalence of Bristol's Sustiva and Gilead's Truvada, which make a new combination treatment for HIV infection in ... - Reuters

Researchers find better HIV medication  Jan 18, 2006
...approved by the US Food and Drug Administration (FDA) in 2001 and 2003 respectively, could be available in a single pill, called Truvada, lead author Joel ... - Xinhua,

Merck, Gilead in integrase-inhibitor race  Jan 13, 2006
...analyst Ron Ellis rated Gilead "underweight" this week based partly on the company's announcement that its triple HIV co-formulation of Truvada and Bristol ... - Science Daily (press release)

More efficient HIV treatment discovered  Jan 24, 2006
He noted that this regimen became even simpler in 2004, when tenofovir and emtricitabine were combined into a single pill, called Truvada. ... - Mmegi,

Study gives high marks to new drugs  Jan 19, 2006
He said the regimen became even simpler in 2004, when tenofovir and emtricitabine were combined into a single pill, called Truvada. ... - United Press International

Science & Medicine | Gilead, Bristol-Myers Squibb Develop Once-a ...  Jan 19, 2006
...into two groups: one group received a one-pill combination of BMS' Sustiva and Gilead's Viread and Emtriva -- already sold together as Truvada -- and the other ... - Kaiser network.org,

Gilead's Truvada Seen Superior To GSK's Combivir  Nov 18, 2005
...maintained an "outperform" rating on Gilead Sciences (nasdaq: GILD - news - people ) after the drug firm reported positive trial results for HIV drug Truvada. ... - Forbes

Gilead posts positive Truvada results  Nov 17, 2005
...said Thursday that preliminary data shows HIV patients who switched to its Truvada therapy from GlaxoSmithKline PLC's Combivir in a recent study had a ... - BusinessWeek

Switching from twice-daily Combivir to once-daily Truvada in ...  Nov 23, 2005
Preliminary 24-week data from the COMET ( Combination of Efavirenz and Truvada ) study were presented at the 10th European AIDS Conference ( EACS ), in Dublin ... - Xagena.it,

Gilead's Truvada Better at Suppressing HIV Than GSK's Combivir ...  Nov 21, 2005
Gilead Sciences' once-daily combination antiretroviral drug Truvada is more effective at suppressing HIV than GlaxoSmithKline's twice-daily antiretroviral ... - Kaiser network.org,

Gilead Posts Positive Truvada Results  Nov 17, 2005
...said Thursday that preliminary data shows HIV patients who switched to its Truvada therapy from GlaxoSmithKline PLC's Combivir in a recent study had a ... - Forbes

*vwd/BUSINESS WIRE: 24-Wochen-Daten zur Wirkung von HIV-Patienten ...  Nov 17, 2005
Gilead Sciences Inc. hat heute die Präsentation der vorläufigen 24-Wochen-Daten der COMET (Kombination von Efavirenz und Truvada)-Studie auf der 10. ... - Vereinigte Wirtschaftsdienste,

Zoek in het archief  Nov 17, 2005
...( BW)(CA-GILEAD-SCIENCES)(GILD) Preliminary 24-Week Data Evaluating the Impact of Switching from Twice-Daily Combivir to Once-Daily Truvada in Patients with ... - Netherlands Corporate News,

Preliminary 24-Week Data Evaluating the Impact of Switching from ...  Nov 17, 2005
...(Nasdaq:GILD) today announced the presentation of preliminary 24-week data from the COMET (Combination of Efavirenz and Truvada) study at the 10th European ... - PharmaLive.com (press release),

Preliminary 24-Week Data Evaluating the Impact of Switching from ...  Nov 17, 2005
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the presentation of preliminary 24-week data from the COMET (Combination of Efavirenz and Truvada) study at ... - Genetic Engineering News,

Gilead Gains a Bit Too Much Respect  Dec 2, 2005
Gilead combined Viread and Emtriva into a single once-a-day pill marketed as Truvada. It received approval in mid-2004. Since then ... - TheStreet.com (subscription),

Merck & Co. HIV Drug Lowers Virus Level and Gilead Posts Positive ...  Nov 21, 2005
Drug maker Gilead Sciences Inc. (Nasdaq:GILD) said Thursday that preliminary data shows HIV patients who switched to its Truvada therapy from GlaxoSmithKline ... - Financial News USA (press release),

Gilead Sciences "buy," target price raised  Nov 14, 2005
...by Roche. The sales estimates for Truvada in out years have been raised to reflect the healthy trends in Truvada scripts. The EPS ... - New Ratings

Gilead Shares Face Limited Upside  Nov 15, 2005
Gilead expects to file for approval of new triple combination formula featuring its Truvada (Viread/Emtriva) and Bristol-Myers Squibb's (nyse: BMY - news ... - Forbes

Stock Scorecard  Nov 13, 2005
GILEAD SCIENCES INC., +8.9 percent to $54.08: The maker of the Truvada HIV drug was rated new "buy" in new coverage by analyst Jennifer Chao at Deutsche Bank. ... - Asbury Park Press,

Aviva, Elan, Glaxo, Reuters, WPP: UK and Irish Equity Preview  Nov 17, 2005
GlaxoSmithKline Plc (GSK LN): Gilead Sciences Inc.'s efforts to win over HIV patients to its Truvada drug from GlaxoSmithKline's Combivir may get a boost with ... - Bloomberg

Montgomery & Co. LLC Announces Investment Opinion: Initiates ...  Dec 1, 2005
It sells five drugs, Truvada, Viread and Emtriva, for HIV treatment; AmBisome, for fungal infections; and Hepsera for chronic hepatitis B infection. ... - Business Wire (press release),

AIDS drugs take financial toll on patients  Dec 1, 2005
But the price tag is high. The three medications the man takes, Reyataz, Truvada and Norvir, have a retail price of close to $2,000 a month — $24,000 a year. ... - The State,

Biotech Earnings Jump In Quarter  Nov 21, 2005
Growth was led by Truvada, which combines the active ingredients emtricita-bine and tenofovir disoproxil fumarate in one pill. Truvada ... - Chemical & Engineering News

Accord on Sharing Flu Vaccine Production  Nov 16, 2005
...compared with the nearly $2 billion the company is expected to receive this year from drugs it sells by itself, particularly the AIDS drugs Viread and Truvada. ... - New York Times,

Gilead's Half-Empty Pipeline  Nov 21, 2005
One is an HIV drug that combines Gilead's Truvada (which itself is a combo of two Gilead drugs to treat HIV) and Sustiva from Bristol-Myers Squibb (nyse: BMY ... - Forbes

Clinically or potentially significant drug interactions between DIFLUCAN and the following agents/classes have been observed. These are described in greater detail below:

DIFLUCAN and the following agents/classes have been observed. These are described in greater detail below:

Oral hypoglycemics
Coumarin-type anticoagulants
Phenytoin
Cyclosporine
Rifampin
Theophylline
Terfenadine
Cisapride
Astemizole
Rifabutin
Tacrolimus
Short-acting benzodiazepines

Oral hypoglycemics: Clinically significant hypoglycemia may be precipitated by the use of DIFLUCAN with oral hypoglycemic agents; one fatality has been reported from hypoglycemia in association with combined DIFLUCAN and glyburide use. DIFLUCAN reduces the metabolism of tolbutamide, glyburide, and glipizide and increases the plasma concentration of these agents. When DIFLUCAN is used concomitantly with these or other sulfonylurea oral hypoglycemic agents, blood glucose concentrations should be carefully monitored and the dose of the sulfonylurea should be adjusted as necessary.

Coumarin-type anticoagulants: Prothrombin time may be increased in patients receiving concomitant DIFLUCAN and coumarin-type anticoagulants. In post-marketing experience, as with other azole antifungals, bleeding events (bruising, epistaxis, gastrointestinal bleeding, hematuria, and melena) have been reported in association with increases in prothrombin time in patients receiving fluconazole concurrently with warfarin. Careful monitoring of prothrombin time in patients receiving DIFLUCAN and coumarin-type anticoagulants is recommended. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.)

Phenytoin: DIFLUCAN increases the plasma concentrations of phenytoin. Careful monitoring of phenytoin concentrations in patients receiving DIFLUCAN and phenytoin is recommended. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.)

Cyclosporine: DIFLUCAN may significantly increase cyclosporine levels in renal transplant patients with or without renal impairment. Careful monitoring of cyclosporine concentrations and serum creatinine is recommended in patients receiving DIFLUCAN and cyclosporine. (See CLINICAL PHARMACOLOGY: Drug Interaction Studies.)

Rifampin: Rifampin enhances the metabolism of concurrently administered DIFLUCAN. Depending on clinical circumstances, consideration should be given to increasing the dose of DIFLUCAN when it is administered with rifampin.

Theophylline: DIFLUCAN increases the serum concentrations of theophylline. Careful monitoring of serum theophylline concentrations in patients receiving DIFLUCAN and theophylline is recommended.

Terfenadine: Because of the occurrence of serious cardiac dysrhythmias secondary to prolongation of the QTc interval in patients receiving azole antifungals in conjunction with terfenadine, interaction studies have been performed. One study at a 200-mg daily dose of fluconazole failed to demonstrate a prolongation in QTc interval. Another study at a 400-mg and 800-mg daily dose of fluconazole demonstrated that DIFLUCAN taken in doses of 400 mg per day or greater significantly increases plasma levels of terfenadine when taken concomitantly. The combined use of fluconazole at doses of 400 mg or greater with terfenadine is contraindicated. The coadministration of fluconazole at doses lower than 400 mg/day with terfenadine should be carefully monitored.

Cisapride: There have been reports of cardiac events, including torsade de pointes in patients to whom fluconazole and cisapride were coadministered. A controlled study found that concomitant fluconazole 200 mg once daily and cisapride 20 mg four times a day yielded a significant increase in cisapride plasma levels and prolongation of QTc interval.The combined use of fluconazole with cisapride is contraindicated.

Astemizole: The use of fluconazole in patients concurrently taking astemizole or other drugs metabolized by the cytochrome P450 system may be associated with elevations in serum levels of these drugs. In the absence of definitive information, caution should be used when coadministering fluconazole. Patients should be carefully monitored.

Rifabutin: There have been reports of uveitis in patients to whom fluconazole and rifabutin were coadministered. Patients receiving rifabutin and fluconazole concomitantly should be carefully monitored.

Tacrolimus: There have been reports of nephrotoxicity in patients to whom fluconazole and tacrolimus were coadministered. Patients receiving tacrolimus and fluconazole concomitantly should be carefully monitored.

Short-acting Benzodiazepines: Following oral administration of midazolam, fluconazole resulted in substantial increases in midazolam concentrations and psychomotor effects. This effect on midazolam appears to be more pronounced following oral administration of fluconazole than with fluconazole administered intravenously. If short-acting benzodiazepines, which are metabolized by the cytochrome P450 system, are concomitantly administered with fluconazole, consideration should be given to decreasing the benzodiazepine dosage, and the patients should be appropriately monitored.

Fluconazole tablets coadministered with ethinyl estradiol- and levonorgestrel-containing oral contraceptives produced an overall mean increase in ethinyl estradiol and levonorgestrel levels; however, in some patients there were decreases up to 47% and 33% of ethinyl estradiol and levonorgestrel levels. The data presently available indicate that the decreases in some individual ethinyl estradiol and levonorgestrel AUC values with fluconazole treatment are likely the result of random variation. While there is evidence that fluconazole can inhibit the metabolism of ethinyl estradiol and levonorgestrel, there is no evidence that fluconazole is a net inducer of ethinyl estradiol or levonorgestrel metabolism. The clinical significance of these effects is presently unknown.

Physicians should be aware that interaction studies with medications other than those listed in the CLINICAL PHARMACOLOGY section have not been conducted, but such interactions may occur.